The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021
Megan Wallace(Centers for Disease Control and Prevention), Sara E. Oliver(Centers for Disease Control and Prevention), Danielle Moulia(Centers for Disease Control and Prevention), Julia W. Gargano(Canadian Institutes of Health Research), Kate R. Woodworth(CDC Foundation), Stephen C. Hadler(The Task Force for Global Health), José R. Romero(Boston University), Grace M. Lee, Heather M. Scobie, Amy Blain, H. Keipp Talbot(Marshfield Clinic), Rebecca L. Morgan(Impact), Beth P. Bell(Centers for Disease Control and Prevention), Mary E. Chamberland, Doug Campos‐Outcalt, Nicole Reisman(American Academy of Family Physicians), Jessica R. MacNeil(Centers for Disease Control and Prevention), Matthew F. Daley(Kaiser Permanente)
Cited by 146
Related Papers
Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020
|MMWR Morbidity and Mortality Weekly Report|2020|2.4k
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
|The Lancet|2019|1.3k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices
|MMWR Morbidity and Mortality Weekly Report|2019|996
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2014
|MMWR Morbidity and Mortality Weekly Report|2015|835